EMP16
Weight-loss maintenance in obesity
Phase 2Active
Key Facts
About Empros Pharma
Empros Pharma is a private, clinical-stage biotech developing EMP16, an oral combination therapy for weight-loss maintenance in obesity. The company, founded by Uppsala University researchers and Flerie Invest, has reported positive Phase 2 topline results (POEM study). It operates with a small, experienced team and a science-driven culture, aiming to address a significant gap in the current obesity treatment landscape.
View full company profile